{"product_id":"ntla-ansoff-analysis","title":"(NTLA) Intellia Therapeutics, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Growth Paths Behind the Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Intellia Therapeutics, Inc. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification to guide strategy, investment, or research decisions. This page contains a real preview\/sample of the analysis so you can inspect format and substance before buying; purchase the full version to receive the complete, ready-to-use Ansoff Matrix report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvance NTLA-2001 in transthyretin amyloidosis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvancing NTLA-2001, Intellia Therapeutics, Inc.’s lead in vivo program, can deepen its foothold in transthyretin amyloidosis, a rare disease that affects about 50,000 people worldwide. Moving the asset through Phase 1 clinical milestones can build visibility with amyloidosis specialists and major treatment centers, and strengthen Intellia’s first-mover profile in gene editing for this segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProgress NTLA-2002 in hereditary angioedema\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNTLA-2002 is Intellia Therapeutics, Inc.'s in vivo hereditary angioedema program, and strong clinical delivery can deepen its standing in this rare-disease niche. Phase 1 data showed up to a 95% mean reduction in monthly attack rate, a clear signal for immunology and allergy specialists. That kind of proof can help Intellia build share in the angioedema treatment field.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand hemophilia A and B co-development with Regeneron\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. is extending its 50\/50 co-development pact with Regeneron Pharmaceuticals into hemophilia A and B, keeping it in a rare bleeding disorder space that affects about 1 in 5,000 male births for hemophilia A and 1 in 25,000 for hemophilia B. Shared development lowers execution risk and can speed clinical trust.\u003c\/p\u003e\n\u003cp\u003eJoint work with a top biopharma name like Regeneron also boosts credibility with hemophilia centers and payers, which matters in a market where one-time gene-editing cures can carry multimillion-dollar pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReinforce liver-directed genome editing programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. is deepening liver-directed genome editing across 3 core programs: hemophilia A, hemophilia B, and hyperoxaluria type 1, with alpha-1 antitrypsin deficiency also in the liver franchise. This concentration lets the Company reuse the same hepatology, hematology, and rare-disease channels, so each new readout can lift adoption in adjacent liver markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame specialist base, higher repeat reach\u003c\/li\u003e\n\u003cli\u003e3 liver programs, one commercial path\u003c\/li\u003e\n\u003cli\u003eAdjacency can lower launch friction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLeverage CRISPR\/Cas9 platform leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. can deepen market penetration by keeping CRISPR\/Cas9 at the center of every program, so the same platform builds name recall across liver and systemic in vivo editing. With 2 lead in vivo programs, NTLA-2001 and NTLA-2002, platform reuse reinforces a single brand story in a market where first movers matter.\u003c\/p\u003e\n\u003cp\u003eThis consistency helps Intellia stay top of mind as in vivo CRISPR moves from proof-of-concept to larger trials and commercial prep, and it supports faster platform learning across 1 core editing engine. The message is simple: one platform, multiple shots on goal.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne CRISPR\/Cas9 platform\u003c\/li\u003e\n\u003cli\u003e2 lead in vivo programs\u003c\/li\u003e\n\u003cli\u003eStronger brand recall\u003c\/li\u003e\n\u003cli\u003eBetter market visibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellia’s Rare-Disease Pipeline Gains Momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. can deepen penetration by pushing NTLA-2001 and NTLA-2002 through late-stage proof in rare diseases, where smaller specialist networks speed adoption. NTLA-2002 showed up to 95% mean monthly attack-rate reduction, and Regeneron-backed hemophilia work expands reach across high-value hematology centers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNTLA-2002\u003c\/td\u003e\n\u003ctd\u003eUp to 95% attack reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNTLA-2001\u003c\/td\u003e\n\u003ctd\u003eTTR amyloidosis focus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHemophilia\u003c\/td\u003e\n\u003ctd\u003e50\/50 Regeneron pact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Intellia Therapeutics, Inc.’s growth strategy through the four core directions of the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise Ansoff Matrix analysis for Intellia Therapeutics, Inc., helping clarify growth options across products and markets for faster strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary, peer-reviewed, regulatory, and company filings to validate Ansoff Matrix growth assumptions for Intellia Therapeutics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMove liver programs into broader rare-disease markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. is using its liver platform across 3 rare-disease programs: hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. That makes this a market development move, because the same base technology can reach new patient groups without building a new platform. The hemophilia market alone still affects about 1.1 million people worldwide, so the addressable rare-disease pool is large.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnter oncology through NTLA-5001 for acute myeloid leukemia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNTLA-5001 is Intellia Therapeutics, Inc.'s ex vivo AML program, so it moves the company into oncology from its liver-focused rare-disease base. AML affects about 20,000 people a year in the U.S., which opens a much larger market. The move reuses Intellia Therapeutics, Inc.'s genome-editing know-how, but with a new commercial path.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReach ophthalmology through SparingVision\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia’s alliance with SparingVision SAS opens ophthalmology as a new market while keeping the same CRISPR\/Cas9 core, so it fits Ansoff’s market development play. The deal adds a second disease area without forcing Intellia to build a new platform, which lowers technical risk and speeds entry. It also taps a rare-disease eye market where over 300 million people live with vision loss worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExpand hematology reach with Novartis collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc.’s work with Novartis Institutes for BioMedical Research on engineered hematopoietic stem cells for sickle cell disease pushes it beyond liver-only editing and into a wider blood-disorder market. Sickle cell disease affects about 8 million people worldwide, so this move opens a large new demand pool. The Novartis tie-up also gives Intellia reach through a global life-sciences partner.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMoves from liver to hematology\u003c\/li\u003e\n\u003cli\u003eTargets sickle cell disease\u003c\/li\u003e\n\u003cli\u003eAccesses Novartis scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBroaden clinical network through Ospedale San Raffaele\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc.'s collaboration with Ospedale San Raffaele broadens access to a top clinical and research network in genomic medicine. That matters for market development because it can open new trial sites, referral paths, and expert communities in Italy and the wider EU.\u003c\/p\u003e\n\u003cp\u003eFor Intellia Therapeutics, Inc., this kind of hospital tie-up can speed enrollment in new treatment settings and raise credibility with physicians who run rare-disease and gene-editing studies. It is a direct way to move beyond current centers and build local adoption for future programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands clinical reach in Italy\u003c\/li\u003e\n\u003cli\u003eAdds research-grade patient access\u003c\/li\u003e\n\u003cli\u003eSupports genomic medicine adoption\u003c\/li\u003e\n\u003cli\u003eStrengthens expert community visibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCRISPR Expansion Opens Huge New Markets for Intellia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. uses the same CRISPR platform to enter new disease markets: hemophilia A\/B, HAE, alpha-1 antitrypsin deficiency, AML, and ophthalmology. That is market development, not new tech. The reach is large: hemophilia affects about 1.1 million people worldwide, AML about 20,000 U.S. cases a year, and sickle cell disease about 8 million globally.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eNTLA-5001\u003c\/td\u003e\n\u003ctd\u003eAML\u003c\/td\u003e\n\u003ctd\u003e20,000 U.S.\/year\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eIntellia Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality, tailored to Intellia Therapeutics’ product-market strategies and growth options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvance NTLA-2002 as a new hereditary angioedema therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNTLA-2002 is Intellia Therapeutics, Inc.’s separate in vivo CRISPR candidate for hereditary angioedema, distinct from NTLA-2001 for transthyretin amyloidosis. Advancing it adds a second rare-disease product to the same franchise and deepens pipeline breadth with another clinical-stage asset. That fits product development in the Ansoff Matrix: new product, same core gene-editing platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuild hemophilia A and B gene-editing candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. and Regeneron are co-developing hemophilia A and B gene-editing candidates, a product development move that extends Intellia's liver-directed editing platform into a larger rare-disease market. Hemophilia affects about 1.1 million people worldwide, but only around 30% are diagnosed, so even modest uptake can matter. The programs broaden product breadth in an established space while targeting durable, one-time treatment potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDevelop hyperoxaluria Type 1 therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia’s liver-focused hyperoxaluria type 1 program is a new product bet in its genome-editing pipeline, moving the company from one rare-disease target to another. Primary hyperoxaluria type 1 affects about 1 to 3 people per 1,000,000, so even small clinical gains can be valuable.\u003c\/p\u003e\n\u003cp\u003eThis fits Ansoff’s product development cell: same platform, new therapy, new clinical use. It also broadens the platform across rare liver diseases, which can spread R\u0026amp;D risk across more shots on goal.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCreate alpha-1 antitrypsin deficiency program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. is extending its in vivo gene-editing platform into alpha-1 antitrypsin deficiency, a separate liver-focused product line that still uses the same core technical engine. That fits product development in the Ansoff Matrix: new product, existing capability set. Alpha-1 antitrypsin deficiency affects about 1 in 2,000 to 1 in 5,000 people of European ancestry, so it adds another rare disease market with real unmet need.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew liver program, same platform\u003c\/li\u003e\n\u003cli\u003eGrows rare-disease pipeline depth\u003c\/li\u003e\n\u003cli\u003eTargets a sizable orphan market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdvance engineered cell therapies for oncology and autoimmune disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. is extending its CRISPR base from liver editing into engineered cell therapies for oncology and autoimmune disease, so this is clear product development. These proprietary programs add new candidates beyond its liver-focused pipeline and reuse the same genome-editing core. The move broadens Intellia Therapeutics, Inc.'s addressable market without changing the platform.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew candidates beyond liver editing\u003c\/li\u003e\n\u003cli\u003eBuilt on the same genome-editing foundation\u003c\/li\u003e\n\u003cli\u003eTargets oncology and autoimmune disease\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellia Expands CRISPR Pipeline With New Rare-Disease Bets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. is using product development to add new CRISPR medicines on its existing platform, especially NTLA-2002, hemophilia, hyperoxaluria type 1, and alpha-1 antitrypsin deficiency. This broadens its rare-disease pipeline without changing the core liver-editing engine.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNTLA-2002\u003c\/td\u003e\n\u003ctd\u003eNew rare-disease product\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHemophilia\u003c\/td\u003e\n\u003ctd\u003e~1.1M global cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnter sickle cell disease with Novartis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc.’s Novartis deal moves it from liver-only in vivo editing into sickle cell disease, a new market and a different modality: engineered hematopoietic stem cells. Sickle cell disease affects about 100,000 people in the U.S. and more than 8 million worldwide, so the addressable pool is larger than Intellia’s current liver-led focus. That makes this a clear diversification step, not just line extension.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMove into ocular genomic medicines with SparingVision\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc.’s alliance with SparingVision moves CRISPR\/Cas9 into ocular disease, opening a new market and a new clinical use beyond liver and hematology programs. That is diversification in the Ansoff sense: new product, new application, same core gene-editing platform. With one platform now spanning at least 3 therapeutic areas, the company lowers concentration risk and widens its addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDevelop AML-directed ex vivo therapy with NTLA-5001\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNTLA-5001 fits Intellia Therapeutics, Inc.'s diversification move into AML, a new oncology market beyond its rare liver disease base. AML is a large, high-need area, with about 20,000 new U.S. cases a year and roughly 30% 5-year survival. The ex vivo format also shifts Intellia Therapeutics, Inc. into a different product and manufacturing model, widening both clinical and operating risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePursue autoimmune cell therapy programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. is diversifying by moving engineered cell therapy programs for autoimmune disease into a new market and a new product class, which is a clear step beyond its in vivo liver-focused CRISPR pipeline. In 2023, Intellia held $909.1 million in cash, cash equivalents, and marketable securities, while R\u0026amp;D expense was $428.6 million, showing it has the capital base to fund this wider bet.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew market: autoimmune disorders\u003c\/li\u003e\n\u003cli\u003eNew product class: engineered cell therapies\u003c\/li\u003e\n\u003cli\u003eDiversifies beyond liver-targeted in vivo editing\u003c\/li\u003e\n\u003cli\u003eBacked by $909.1 million cash in 2023\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLeverage CRISPR\/Cas9 across multiple disease classes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. uses one platform, but it can open several markets at once: in vivo and ex vivo CRISPR\/Cas9 editing. That is diversification in Ansoff terms, because the same core tech can move into hematology, oncology, ophthalmology, and autoimmune disease, not just one therapy lane. In 2025, the company still had no product revenue and was funding this reach with a cash runway built for R\u0026amp;D-heavy expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne platform, many disease classes\u003c\/li\u003e\n\u003cli\u003eIn vivo plus ex vivo reach\u003c\/li\u003e\n\u003cli\u003eMultiple new market-product pairs\u003c\/li\u003e\n\u003cli\u003eHigh risk, high optionality strategy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellia Expands Beyond Liver Editing, Betting Cash on New CRISPR Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc.’s diversification is clear: it is moving CRISPR\/Cas9 from liver editing into hematology, oncology, ophthalmology, and autoimmune disease. That is a new product-market mix in Ansoff terms, with lower concentration risk but higher R\u0026amp;D and execution risk. The company had no product revenue in 2025, so this remains a cash-funded growth bet.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket reach\u003c\/td\u003e\n\u003ctd\u003e4 disease areas\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234765218057,"sku":"ntla-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/ntla-ansoff-matrix.webp?v=1785726790","url":"https:\/\/dcfanalyst.com\/products\/ntla-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}